Cabozantinib in Progressive Medullary Thyroid Cancer

PURPOSE: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. PATIENTS AND METHOD...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Elisei, Rossella, Schlumberger, Martin J., Müller, Stefan P., Schöffski, Patrick, Brose, Marcia S., Shah, Manisha H., Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C., Niederle, Bruno, Cohen, Ezra E.W., Wirth, Lori J., Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, Sherman, Steven I.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164813/
https://ncbi.nlm.nih.gov/pubmed/24002501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.48.4659
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares